Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

BACKGROUND: Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg, have not been compared as initial antiretroviral treatment. To address this data gap, we conducted an open-label, multicenter 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Kimberly Y, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365957/
https://www.ncbi.nlm.nih.gov/pubmed/18373851
http://dx.doi.org/10.1186/1742-6405-5-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365957/
https://www.ncbi.nlm.nih.gov/pubmed/18373851
http://dx.doi.org/10.1186/1742-6405-5-5

Ejemplares similares